Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Ravi K. Amaravadi, MD

Ravi K. Amaravadi, MD Physician

Associate Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Amaravadi is a Penn Medicine employed physician.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Patient Comments

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Medical Oncology, 2006

Clinical Expertise:

  • Melanoma
  • Skin Cancer

Description of Clinical Expertise

Phase I and Phase II Clinical Trials
Melanoma

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Johns Hopkins University School of Medicine
Residency: Brigham and Women's Hospital
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Association for Cancer Research, National American Association for the Advancement of Science, National American Society of Clinical Oncology, National Austrian Science Fund (FWF),, International Beyond Batten Disease Foundation, International Health Research Ireland, International Icelandic Research Fund, International Immunaccel Biosciences, National Melanoma Research Foundation Breakthrough Consortium, National Melanoma Research Foundation, National NCI -J special emphasis panel study section for K awards, National Newcastle University, UK, International NIH Loan repayment program, National Presage Biosciences, National Sprint Biosciences, International Wistar Institute, Cancer Center, Tumor Microenvironment and Metastases Program, Local

Hospital Affiliation

Dr. Amaravadi is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Selected Publications:

Kong Jianping, Whelan Kelly A, Laczkó Dorottya, Dang Brendan, Caro Monroig Angeliz, Soroush Ali, Falcone John, Amaravadi Ravi K, Rustgi Anil K, Ginsberg Gregory G, Falk Gary W, Nakagawa Hiroshi, Lynch John P: Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. Molecular carcinogenesis 55 (11): 1526-1541,2016.

Zhang Gao, Frederick Dennie T, Wu Lawrence, Wei Zhi, Krepler Clemens, Srinivasan Satish, Chae Young Chan, Xu Xiaowei, Choi Harry, Dimwamwa Elaida, Ope Omotayo, Shannan Batool, Basu Devraj, Zhang Dongmei, Guha Manti, Xiao Min, Randell Sergio, Sproesser Katrin, Xu Wei, Liu Jephrey, Karakousis Giorgos C, Schuchter Lynn M, Gangadhar Tara C, Amaravadi Ravi K, Gu Mengnan, Xu Caiyue, Ghosh Abheek, Xu Weiting, Tian Tian, Zhang Jie, Zha Shijie, Liu Qin, Brafford Patricia, Weeraratna Ashani, Davies Michael A, Wargo J: Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. The Journal of clinical investigation 126 (5): 1834-56,2016.

Budina-Kolomets Anna, Webster Marie R, Leu Julia I-Ju, Jennis Matthew, Krepler Clemens, Guerrini Anastasia, Kossenkov Andrew V, Xu Wei, Karakousis Giorgos, Schuchter Lynn, Amaravadi Ravi K, Wu Hong, Yin Xiangfan, Liu Qin, Lu Yiling, Mills Gordon B, Xu Xiaowei, George Donna L, Weeraratna Ashani T, Murphy Maureen E: HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer research 76 (9): 2720-30,2016.

Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, Xu B, Dada H, Odiorizzi P, Herati R, Mansfield K, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma D, Xu X, Feldman M, Gangadhar T, Hahn S, Wherry JE, Vonderheide R, Benci J, Minn A.: Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer Nature : 2015.

Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA.: A Phase 1 Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular Cancer Therapeutics : 2015.

Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR.: Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research : 2015.

Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ.: Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. The Oncologist : 2015.

Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis GC, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res. : 2015.

Krayya A, Piao S, Xu G, Zhang G, Gimotty PG, Xu X, Amaravadi RK**, Speicher DW**. **Co-senior authors.: Identification of secreted proteins that reflect autophagy dynamics with tumor cells Autophagy 11 (1): 60-74,2015.

Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB.: Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer 51 (11): 1435-43,2015.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-201
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 662-7402
Fax: (215) 349-8550
Patient appointments: 800-789-PENN (7366)

Related Links